Opinion: MAHA is rewriting the vocabulary of American mental health care
Impact on your practice
Federal deprescribing initiatives create new clinical and billing opportunities for therapists while potentially pressuring prescribing practices. Therapists should understand the evidence, reimbursement rules, and ethical considerations around medication tapering to protect clients and navigate changing clinical norms.
Key facts
HHS under RFK Jr. promoting psychiatric deprescribing as policy priority
SAMHSA developing clinical guidance on tapering SSRIs and other antidepressants
Medicare clarifying reimbursement for deprescribing as clinical service
Represents significant rhetorical and policy shift in federal mental health approach
Therapy Companion analysis
The federal deprescribing initiative creates both clinical and financial complexity for your practice. While Medicare has begun clarifying reimbursement for deprescribing as a billable clinical service, the policy shift signals that insurers may increasingly scrutinize psychiatric medication use and potentially deny coverage for maintenance antidepressant therapy—particularly for patients without severe, persistent mental illness diagnoses. This means you should expect referrals from prescribers seeking to taper patients off SSRIs and other medications, but you'll need to document clinical justification carefully. Your reimbursement depends on demonstrating that deprescribing is medically necessary and that you're providing active therapeutic intervention during the tapering process, not simply monitoring. The risk: if you bill for deprescribing support without robust clinical documentation showing active treatment (e.g., CBT, DBT skills, relapse prevention), denials will increase. Additionally, if your state Medicaid program adopts deprescribing guidelines aligned with federal policy, prior authorization requirements may shift—some states may require approval before continuing antidepressants, forcing you into a gatekeeper role. Solo practitioners and small group practices should anticipate increased administrative burden as payers demand evidence that medication reduction is clinically appropriate before authorizing continued therapy billing.
Background
The Trump administration's appointment of Robert F. Kennedy Jr. to lead HHS has accelerated a significant rhetorical and policy reorientation toward psychiatric deprescribing—the planned, evidence-based reduction or discontinuation of psychiatric medications. This represents a departure from decades of parity advocacy that focused on expanding access to medication-assisted treatment and ensuring insurance coverage for psychiatric care. SAMHSA's development of clinical guidance on tapering SSRIs and other antidepressants signals that federal agencies are now actively promoting medication reduction as a clinical priority, not merely as an option for individual patients. This shift reflects broader skepticism about long-term psychiatric medication use and aligns with anti-pharmaceutical rhetoric that has gained political traction. For therapists, this creates a paradox: while deprescribing can be clinically appropriate for some patients, the federal policy momentum may pressure prescribers to deprescribe prematurely and may incentivize insurers to deny medication coverage, potentially harming patients who benefit from pharmacotherapy.
What you should do
Review your current patient caseload and identify clients on long-term antidepressants or other psychiatric medications. Document your clinical rationale for continued medication use (e.g., relapse history, symptom severity, failed prior tapering attempts) to prepare for potential insurance challenges or prescriber requests to deprescribe.
Obtain training in evidence-based deprescribing protocols (e.g., SSRI tapering schedules, withdrawal symptom monitoring, relapse prevention) so you can competently support patients through medication reduction if clinically indicated and can bill appropriately for this service.
Clarify with your major payers (Medicare, state Medicaid, commercial insurers) whether deprescribing support is a reimbursable service, what documentation is required, and whether prior authorization is needed. Request written guidance to protect yourself against retroactive denials.
Establish clear communication protocols with prescribers in your referral network about your role during deprescribing. Ensure you have written agreements specifying who monitors for withdrawal symptoms, who makes tapering decisions, and how you'll document shared clinical decision-making.
Monitor state Medicaid program updates and professional association guidance (NASW, APA, AAMFT) for emerging deprescribing policies and billing rules. Federal policy shifts often cascade to state programs within 12-18 months, so early awareness will help you adjust documentation and billing practices proactively.
Notable excerpts
HHS under RFK Jr. promoting psychiatric deprescribing as policy priority; SAMHSA developing clinical guidance on tapering SSRIs and other antidepressants.
Medicare clarifying reimbursement for deprescribing as clinical service—represents significant rhetorical and policy shift in federal mental health approach.
Policy changes drive denial patterns
Therapy Companion tracks both: the policy shifts on this page and the denial patterns hitting your claims.
Related policy changes
[MA] H4895: Expanding access to mental health services
This bill aims to expand mental health service access in Massachusetts and has cleared committee with a favorable recommendation. Depending on final language, it could affect reimbursement rates, telehealth authorization, or insurance coverage requirements.
[TN] SB1248: AN ACT to amend Tennessee Code Annotated, Title 4; Title 8; Title 33; Title 39; Title 49; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to mental health.
This comprehensive TN mental health bill touches multiple code sections and could affect licensure, scope of practice, insurance requirements, and workforce regulations. Therapists should monitor its progress closely as it moves through committee.
Advancing the Future of Behavioral Health Data Exchange
This policy direction addresses a critical pain point for therapists: the lack of integrated health data exchange with primary care and medical providers. Improved interoperability could reduce documentation burden, improve care coordination, and reduce liability from medication interactions or missed diagnoses. However, it may also increase compliance requirements and data security obligations.
[WA] HB2720: Increasing access and resources for behavioral health emergency services providers by imposing a covered lives assessment on specific health plans.
Washington's bill to fund behavioral health emergency services through a covered lives assessment is advancing and could reshape how crisis services are financed and accessed. Therapists may see increased referral volume to emergency services and changes in insurance plan structures.